Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Abacavir/Lamivudine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Abacavir/Lamivudine | ACTIVE_COMPARATOR | - |
| Lersivirine + Abacavir/Lamivudine | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Abacavir/Lamivudine | DRUG | Abacavir/Lamivudine 600/300 mg QD for 5 days |
| Lersivirine | DRUG | Lersivirine 750 mg QD for 10 days |
Inclusion Criteria: * Healthy male and/or female subjects. * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2. * Total body weight \>50 kg (110 lbs). Exclusion Criteria: * History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL...
Abacavir/Lamivudine is a small molecule drug being studied in healthy volunteers. It is currently in Phase 1 clinical development. The drug is being investigated for its potential effects in healthy subjects, as part of early-stage research.
Abacavir/Lamivudine is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. The company is conducting early-stage clinical research on this drug in healthy volunteers.
Abacavir/Lamivudine is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in healthy volunteers as part of early-stage research.
Abacavir/Lamivudine has one completed clinical trial, NCT01220232, titled "Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects." This Phase 1 study enrolled 14 participants in the United States and was an active-controlled trial.
No, Abacavir/Lamivudine is not the same as Lersivirine. In the clinical trial NCT01220232, Lersivirine was studied for its effect on the pharmacokinetics of Abacavir/Lamivudine. Abacavir/Lamivudine is a combination drug being investigated in healthy volunteers.